Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

Evotec SE. (3/25/20). "Press Release: Evotec Partner Forge Enters into Collaboration with Roche to Develop Novel Antibiotic". San Diego, CA.

Organisations Organisation Evotec SE (FSE: EVT, MDA X/TecDAX)
  Group Evotec (Group)
  Organisation 2 F. Hoffmann-La Roche AG (CH)
  Group Roche (Group)
Products Product antibiotic
  Product 2 drug development
Index terms Index term Forge Therapeutics–Evotec: drug discovery services, 201612– collab strategic alliance lead optimisation of LpxC inhibitors by Evotec
  Index term 2 Roche–Forge Therapeutics: antibiotics, 202003– collab research + license option up to $190.5m for FG-LpxC LUNG program for lung infections
     


Evotec’s partner Forge Therapeutics, Inc. (“Forge”) today announced a research collaboration and option agreement with Hoffmann-La Roche Ltd. (“Roche”) to license one of its novel antibiotics for the treatment of hospital-based lung infections. The targeted infections includes those cited on the CDC’s most urgent threats list, which commonly occur in people with weakened immune systems and chronic lung diseases.

Under the terms of the agreement, Roche has an exclusive option to license one of Forge’s antibiotic programmes . Forge will retain control of the programme prior to Roche exercising its option, at which time Roche will take over the further development. Forge is eligible to receive $ 190.5 m in total payments and potential sales-based payments and royalties upon commercialisation of the programme.

Evotec is a minority stakeholder in Forge Therapeutics. Over the past years, both companies have collaborated on a number of projects. Evotec has supported the development of Forge’s antibiotic programmes right from the start with essential discovery and development services. The progress of the companies’ alliance enabled Forge to win several Carb-X awards totalling over $ 20 m to support the successful development antibiotic programmes through to pre-clinical development stage.

Please follow this link for the full version of Forge’s press release.

   
Record changed: 2020-04-06

Advertisement

Picture [iito] – Putting Information into Context 650x65px

More documents for Evotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px




» top